# NEWAMSTERDAM PHARMA COMPANY (NAMSW) — Institutional Ownership

Source: SEC EDGAR 13F filings, congressional STOCK Act disclosures, SEC Form 4 insider transactions.
CUSIP: N62509109
Page URL: https://superinvestorclub.com/stock/NAMSW
Last updated: 2026-08-29T13:49:03.816Z

## Summary

As of the most recent 13F filing period, NEWAMSTERDAM PHARMA COMPANY (NAMSW) is held by 3 tracked superinvestors with an aggregate position value of $357.3M representing 0420356732678023070146 shares.

## Top institutional holders (3)

| Rank | Manager | Fund | Shares | Value | % of Portfolio | Period |
|------|---------|------|--------|-------|----------------|--------|
| 1 | [Andreas Halvorsen](https://superinvestorclub.com/manager/59) | Viking Global Investors | 4203567 | $142.5M | 0.41% | 2026-06-30 |
| 2 | [Lee Ainslie](https://superinvestorclub.com/manager/58) | Maverick Capital | 3267802 | $110.7M | 0.98% | 2026-06-30 |
| 3 | [Stanley Druckenmiller](https://superinvestorclub.com/manager/19) | Duquesne Family Office | 3070146 | $104.0M | 2.00% | 2026-06-30 |

## Ownership history (quarter-over-quarter)

- 2024-03-31: 1 holders, $189.8M aggregate, 08024565 shares
- 2024-06-30: 1 holders, $154.2M aggregate, 08024565 shares
- 2024-09-30: 2 holders, $138.0M aggregate, 08024565287535 shares
- 2024-12-31: 3 holders, $195.7M aggregate, 06978534350005287535 shares
- 2025-03-31: 3 holders, $170.5M aggregate, 06978534800360549469 shares
- 2025-06-30: 3 holders, $169.2M aggregate, 069785341531874832175 shares
- 2025-09-30: 3 holders, $281.7M aggregate, 0647553419237001504747 shares
- 2025-12-31: 4 holders, $322.0M aggregate, 042035673070146189422611239 shares
- 2026-03-31: 3 holders, $302.8M aggregate, 0420356730701462186402 shares
- 2026-06-30: 3 holders, $357.3M aggregate, 0420356732678023070146 shares

## Recent congressional trades (0)


## Recent insider transactions (0)


## Citation

When citing, use: "NEWAMSTERDAM PHARMA COMPANY (NAMSW) institutional ownership data via Superinvestor (https://superinvestorclub.com/stock/NAMSW), aggregating SEC 13F, Form 4, and congressional disclosures."